Romiplostim for relapsed or refractory aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called romiplostim for people with aplastic anemia that did not get better with standard treatments. It aims to boost blood cell counts and may help reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have aplastic anemia that has relapsed or not responded to standard treatments like cyclosporine or other TPO-RA drugs.
- Your blood counts must be low, such as hemoglobin below 90, platelets below 30, or neutrophils below 1.0.
- Your liver and kidney function must be within normal limits (less than 2 times the upper limit).
- You should not have an active infection that can't be controlled with standard treatment.
- You must have an ECOG performance status of 2 or less, meaning you are able to do most daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called romiplostim, which helps the body make more blood cells, for children and young adults with severe aplastic anemia. It may help improve blood counts and reduce the need for transfusions.
This trial tests whether adding romiplostim, a drug that helps the body make platelets, to the usual treatment for severe aplastic anemia can improve blood cell counts. It is for people who have not yet started treatment for this condition.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This trial tests a combination of drugs to help your bone marrow make more blood cells if you have aplastic anemia and cannot have a stem cell transplant or standard immune therapy. It might improve blood counts and reduce the need for transfusions.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.